Variational AI will participate in Discovery on Target (DOT) 2026, a leading conference dedicated to the latest advances in drug targets and enabling technologies for therapeutic discovery.
Held annually in Boston, Discovery on Target brings together scientists from pharma, biotech, and academia to explore emerging approaches for identifying and validating novel drug targets, as well as technologies that accelerate the development of new therapeutics.
Advancing the Next Generation of Drug Targets
The conference highlights cutting-edge research across a wide range of therapeutic modalities and technologies, including small molecules, biologics, and next-generation drug discovery platforms. Discussions focus on target identification, validation strategies, and emerging technologies that enable the discovery of innovative therapeutic agents.
With multiple parallel tracks, workshops, and networking opportunities, Discovery on Target provides a platform for researchers and technology innovators to exchange ideas and build collaborations across the drug discovery ecosystem.
Meet with Variational AI at the event
Peter (Pete) Guzzo, EVP of Drug Discovery, will be attending Discovery on Target 2026 to connect with scientists and industry partners interested in AI-driven approaches to small-molecule drug discovery.
If you are attending the conference and would like to learn more about our generative molecular design platform, we would welcome the opportunity to meet.